Global Ovarian Cancer Drugs Market By Therapy (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global ovarian cancer drugs market accounted for $2,283.8 million in 2021, and is expected to reach $5,063.59 million by 2031, registering a CAGR of 8.4% from 2022 to 2031.

Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue. The female reproductive system contains two ovaries, one on each side of the uterus. Each ovary, which is about the size of an almond, produces Egg (ova) along with the hormones progesterone and estrogen. Ovarian cancer treatment usually involves surgery and chemotherapy. Signs and symptoms of ovarian cancer may include abdominal bloating or swelling, quickly feeling full when eating, weight loss, discomfort in pelvic area, fatigue, back pain, changes in bowel habits and a frequent need to urinate.

It is estimated that ovarian cancer drugs market is expected to experience significant growth during the forecast period owing to increase in aging population of women, rise in prevalence of ovarian cancer, launch of innovative medications, boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D, presence of robust pipeline candidates, and increase in public awareness about the disease prevention in developing regions further facilitate the growth of the market. However, high cost of drug development and threat of failure are expected to impede the market growth. In contrast, advancement of cancer research and personalized medicine approach are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the ovarian cancer drugs market.

The ovarian cancer drugs market is segmented on the basis of therapy, distribution channel and region. Depending on therapy, the market is classified into chemotherapy, targeted therapy and others. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global ovarian cancer drugs market. The key companies profiled in the report include AbbVie, Pfizer, Inc., Merck Kagan, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Clovis Oncology, and Amgen.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global ovarian cancer drugs market analysis from 2021 to 2031 to identify the prevailing global ovarian cancer drugs market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the global ovarian cancer drugs market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global global ovarian cancer drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Therapy

Chemotherapy
Targeted Therapy
- Drug Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- Others
Others

By Distribution Channel

Hospital Pharmacy
Drug Stores and Retail Pharmacy
Online Providers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Abbvie Inc
- Pfizer, Inc.
- Merck KGaA
- AstraZeneca
- F. Hoffmann-La Roche AG
- Clovis Oncology
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc

Product Code: A00273

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Chemotherapy
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
4.3 Targeted Therapy
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- 4.3.4 Targeted Therapy Global Ovarian Cancer Drugs Market by Drug Class
4.4 Others
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country

CHAPTER 5: GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Hospital Pharmacy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
5.3 Drug Stores and Retail Pharmacy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
5.4 Online Providers
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country

CHAPTER 6: GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION

6.1 Overview
- 6.1.1 Market size and forecast
6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Therapy
- 6.2.3 North America Market size and forecast, by Distribution Channel
- 6.2.4 North America Market size and forecast, by country
  - 6.2.4.1 U.S.
  - 6.2.4.1.1 Key market trends, growth factors and opportunities
  - 6.2.4.1.2 Market size and forecast, by Therapy
  - 6.2.4.1.3 Market size and forecast, by Distribution Channel
  - 6.2.4.2 Canada
  - 6.2.4.2.1 Key market trends, growth factors and opportunities
  - 6.2.4.2.2 Market size and forecast, by Therapy
  - 6.2.4.2.3 Market size and forecast, by Distribution Channel
  - 6.2.4.3 Mexico
  - 6.2.4.3.1 Key market trends, growth factors and opportunities
  - 6.2.4.3.2 Market size and forecast, by Therapy
  - 6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Therapy
- 6.3.3 Europe Market size and forecast, by Distribution Channel
- 6.3.4 Europe Market size and forecast, by country
  - 6.3.4.1 Germany
  - 6.3.4.1.1 Key market trends, growth factors and opportunities
  - 6.3.4.1.2 Market size and forecast, by Therapy
  - 6.3.4.1.3 Market size and forecast, by Distribution Channel
  - 6.3.4.2 France
  - 6.3.4.2.1 Key market trends, growth factors and opportunities
  - 6.3.4.2.2 Market size and forecast, by Therapy
  - 6.3.4.2.3 Market size and forecast, by Distribution Channel
  - 6.3.4.3 UK
  - 6.3.4.3.1 Key market trends, growth factors and opportunities
  - 6.3.4.3.2 Market size and forecast, by Therapy
  - 6.3.4.3.3 Market size and forecast, by Distribution Channel
  - 6.3.4.4 Italy
  - 6.3.4.4.1 Key market trends, growth factors and opportunities
  - 6.3.4.4.2 Market size and forecast, by Therapy
  - 6.3.4.4.3 Market size and forecast, by Distribution Channel
  - 6.3.4.5 Spain
  - 6.3.4.5.1 Key market trends, growth factors and opportunities
  - 6.3.4.5.2 Market size and forecast, by Therapy
  - 6.3.4.5.3 Market size and forecast, by Distribution Channel
  - 6.3.4.6 Rest of Europe
  - 6.3.4.6.1 Key market trends, growth factors and opportunities
  - 6.3.4.6.2 Market size and forecast, by Therapy
  - 6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Therapy
- 6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
- 6.4.4 Asia-Pacific Market size and forecast, by country
  - 6.4.4.1 Japan
  - 6.4.4.1.1 Key market trends, growth factors and opportunities
  - 6.4.4.1.2 Market size and forecast, by Therapy
  - 6.4.4.1.3 Market size and forecast, by Distribution Channel
  - 6.4.4.2 China
  - 6.4.4.2.1 Key market trends, growth factors and opportunities
  - 6.4.4.2.2 Market size and forecast, by Therapy
  - 6.4.4.2.3 Market size and forecast, by Distribution Channel
  - 6.4.4.3 Australia
  - 6.4.4.3.1 Key market trends, growth factors and opportunities
  - 6.4.4.3.2 Market size and forecast, by Therapy
  - 6.4.4.3.3 Market size and forecast, by Distribution Channel
  - 6.4.4.4 India
  - 6.4.4.4.1 Key market trends, growth factors and opportunities
  - 6.4.4.4.2 Market size and forecast, by Therapy
  - 6.4.4.4.3 Market size and forecast, by Distribution Channel
  - 6.4.4.5 South Korea
  - 6.4.4.5.1 Key market trends, growth factors and opportunities
  - 6.4.4.5.2 Market size and forecast, by Therapy
  - 6.4.4.5.3 Market size and forecast, by Distribution Channel
  - 6.4.4.6 Rest of Asia-Pacific
  - 6.4.4.6.1 Key market trends, growth factors and opportunities
  - 6.4.4.6.2 Market size and forecast, by Therapy
  - 6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Therapy
- 6.5.3 LAMEA Market size and forecast, by Distribution Channel
- 6.5.4 LAMEA Market size and forecast, by country
  - 6.5.4.1 Brazil
  - 6.5.4.1.1 Key market trends, growth factors and opportunities
  - 6.5.4.1.2 Market size and forecast, by Therapy
  - 6.5.4.1.3 Market size and forecast, by Distribution Channel
  - 6.5.4.2 Saudi Arabia
  - 6.5.4.2.1 Key market trends, growth factors and opportunities
  - 6.5.4.2.2 Market size and forecast, by Therapy
  - 6.5.4.2.3 Market size and forecast, by Distribution Channel
  - 6.5.4.3 South Africa
  - 6.5.4.3.1 Key market trends, growth factors and opportunities
  - 6.5.4.3.2 Market size and forecast, by Therapy
  - 6.5.4.3.3 Market size and forecast, by Distribution Channel
  - 6.5.4.4 Rest of LAMEA
  - 6.5.4.4.1 Key market trends, growth factors and opportunities
  - 6.5.4.4.2 Market size and forecast, by Therapy
  - 6.5.4.4.3 Market size and forecast, by Distribution Channel

CHAPTER 7: COMPANY LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments

CHAPTER 8: COMPANY PROFILES

8.1 F. Hoffmann-La Roche AG
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
8.2 Johnson & Johnson Services, Inc.
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
8.3 GlaxoSmithKline Plc
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
8.4 Boehringer Ingelheim International GmbH
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
8.5 Clovis Oncology
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
8.6 Abbvie Inc
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
8.7 Pfizer, Inc.
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
8.8 Merck KGaA
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
8.9 AstraZeneca
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
8.10 Amgen Inc.
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments